Farxiga Would Be 'Breakthrough' for CKD; Thyroid Pills Recalled

(MedPage Today) -- Dapagliflozin (Farxiga) was granted breakthrough therapy designation by the FDA for chronic kidney disease in patients without type 2 diabetes, AstraZeneca announced.
President Trump's obesity status is one factor that may put...